



Partners in Cancer Care

Curriculum Vitae

Stacey Teicher, AOCNP

4721 Dallas Ranch Road, Antioch, CA, 94531 | T: (925) 778-0679 | F: (925) 778-3567

www.epic-care.com

Additional Offices

400 Taylor Boulevard, Suite 201, Pleasant Hill, CA 94523 T: (925) 687-2570

Education

- 1993 Bachelors of Science in Nursing, San Jose State University, San Jose, CA
- 1998 Masters of Science in Nursing, University of Maryland, Baltimore, MD

Professional Experience

- 2005-Present NP, East Bay Medical Oncology-Hematology Associates / Epic Care, Antioch, CA & Pleasant Hill, CA
- 1999-2004 Pediatric Oncology Nurse Practitioner, Lucile Salter Packard Children's Hospital, Palo Alto, CA
- 1995-1999 Army Nurse, United States Army, Walter Reed Medical Center, Washington D.C.
- 1993-1994 RN Night Supervisor, St Elizabeth/St Josephs, San Francisco, CA

Certifications

- Advance Certified Oncology Nurse Practitioner
- Certified Pediatric Nurse Practitioner
- Registered Nurse
- Clinical Nurse Specialist

Medical Licensure

Licensed in California

Affiliations/Hospital Privileges

- Sutter Delta Medical Center, Antioch, CA
- Palo Alto Medical Foundation, Palo Alto, CA

Honors and Awards

Army Achievement Medal. Awarded for strong clinical skills, leadership in various roles, and expert pediatric nursing care.

Memberships

California Association for Nurse Practitioners
Oncology Nursing Society

Committees/Professional Activities

2001-Present Clinical Preceptor for the University of San Francisco, School of Nursing, Family Nurse
1997-1998 Clinical Nurse Preceptor for new ICU graduates at Walter Reed Army Medical Center, pediatric intensive care
1997-1998 Intensive Care Nursing Instructor, Instructed ICU students on pediatric procedures, invasive devices, and assisted in the pediatric skills lab

Publications

MyDoc: Personalized Information For You On Bone Metastases and Zometa, Featuring Stacey Teicher, NP. Novartis Pharmaceuticals, 2010. DVD

My CML Circle: A Patient Education Initiative For PH + CML Patients, Featuring Stacey Teicher, NP. Novartis Pharmaceuticals, 2009. DVD

MyDoc: On Iron Overload, Featuring Stacey Teicher, NP. Novartis Pharmaceuticals, 2008. DVD

MyDoc: Personalized Information For You on Breast Cancer & Femara, Featuring Stacey Teicher, NP. Novartis Pharmaceuticals, 2008. DVD

Emerging Role of the Pediatric Nurse Practitioner in Acute Care *Pediatric Nursing*. 27(4), 387-390

Research Experiences

2005-Present Investigator, Bay Area Cancer Research Group, Pleasant Hill, CA

Randomized Phase III Trial of XXX Injection for The Treatment of Brain Metastases in Patients with NSCLC Undergoing Whole Brain Radiation Therapy.

Prospective Observational Study of XXX in Usual Care.

A Randomized, Double-Blind, Placebo-Controlled, Multi-center Phase III Study Comparing XXX and XXX vs. XXX In Subjects with Estrogen/Progesterone Receptor-Positive Advanced or Metastatic Breast Cancer.

Randomized Study of XXX vs XXX plus XXX in Patients with Previously Treated NSCLC.

Clinical Outcomes in Patients with XXX Amplified Metastatic Breast Cancer Treated with XXX in Combination with A XXX: A Phase IV, Prospective, Community-Based Study.

A Phase III Randomized Study of Three Different Doses of Weekly XXX as First-Line Treatment of Metastatic Breast Cancer.

Phase III Study in Patients with Metastatic Colorectal Cancer Receiving First-line Chemotherapy with XXX and XXX or Placebo.

Phase III Study of XXX vs. XXX or XXX as Third-Line Therapy in Platinum Refractory or Resistant Ovarian.

Phase II Trial comparing XXX to the Combination XXX in Post-menopausal Patients with ER AND/ORPR Metastatic Breast Cancer .

A Multi-Center Randomized Study of XXX, XXX and XXX vs XXX, XXX, XXX, and XXX in Patients with Multiple Myeloma.

A Phase III, Randomized, Double-Blind, Multi-center Trial of XXX Plus Chemotherapy vs Chemotherapy Alone in Patients with Advanced NSCLC Who Have Not Received Prior Chemotherapy.

A Phase I-II, 24-Week, Multi-center, Double-Blind, Randomized Dose Ranging Study to Evaluate the Safety and Efficacy of a Humanized Monoclonal Antibody to XXX vs. XXX in Patients with Breast Cancer Metastatic to Bone.

A Phase III, Double-Blind, Multi-center, Randomized Study in Chemonaive Patients with Locally Advanced or Metastatic Pancreatic Cancer to Compare a Combination Therapy of XXX plus XXX vs, XXX plus XXX.

A Phase II, Randomized, Open-label, Controlled, Dose-Evaluation, Multi-center Trial of XXX for the Prevention of Diarrhea Associated with XXX/XXX in Patients with Previously Untreated Metastatic Colorectal Cancer.

An Open-Label, Randomized, Multi-center Study to Evaluate the Use of XXX in The Prevention of Cancer Treatment-Related Bone Loss in Postmenopausal Women with ER+ and/or PR+ Breast Cancer Receiving XXX.

A Multi-center, Open-Label Study of XXX, XXX and XXX in The Treatment of Previously Untreated and Treated, Stage III or IV, Low-Grade B-Cell Non-Hodgkin's Lymphoma.

A Multi-center, Open-Label Study of XXX, XXX and XXX in Patients with Previously Untreated Chronic Lymphocytic Leukemia.

Randomized Phase III Trial Comparing XXX vs XXX in Chemotherapy-Naïve Patients with Advanced or Metastatic Non-Small Cell Lung Cancer.

Randomized Study of XXX vs XXX in Patients with Previously Treated Non-Small Cell Lung Cancer.

A Phase Ib/II, Open Label Study of the Safety, Pharmacokinetics and Efficacy of XXX Administered Intravenously in Combination with XXX to Subjects with Follicular and Other Low-Grade, CD20-Positive, B-Cell Non-Hodgkin's Lymphomas that have Progressed Following Previous XXX Therapy.

A Randomized, Open Label Multi-Center Study of XXXX at 25 mg in Combination with Prednisone Every 3 Weeks Compared to Mitoxantrone in Combinations with Prednisone for the Treatment of Hormone Refractory Metastatic Prostate Cancer Previously Treated with a Taxotere-Containing Regimen.

A Treatment Protocol for Patients Continuing From Prior XXX Protocol.

Multi-center, Two-Stage Study to Evaluate The Safety and Efficacy of Second-Line Metastatic Colorectal Carcinoma Treatment with Recombinant XXX.

An Open-Label Phase II Study of Weekly Intravenous XXX and Carboplatin as First-Line Treatment of Chemonaive Subjects with Extensive Disease Small Cell Lung Cancer.

A Multi-center, Open-Label, Single-Arm, Two-Stage Study of the Efficacy and Safety of XXX Administered Intravenously Every 2 Weeks in Patients with Platinum and Erlotinib-resistant, Locally Advanced or Metastatic Non-Small-Cell Lung Adenocarcinoma.

Randomized, Double-Blind, Phase 2 Study of Erlotinib with or without XXX in the Treatment of Metastatic Non-Small Cell Lung Cancer.

A Phase III, Multi-center, Placebo-Controlled, Double-Blind, Randomized Clinical Trial to Evaluate the Efficacy of XXX in Combination with XXX Compared with XXX Alone for Treatment of Advanced Non-Small Cell Lung Cancer After Failure of Standard First-Line Chemotherapy.

Phase 2 Randomized, Non-Comparative Study of XXX or Best Supportive Care Immediately Following First-Line, Platinum-Based Therapy in Patients with Stage IIIB (with effusion) or Stage IV Non-Small Cell Lung Cancer That Has Responded or Remained Stable.

A Randomized, Double-blind, Placebo-Controlled, Phase IIIB Trial Comparing XXX Therapy with or without XXX after Completion of Chemotherapy with XXX for the First-Line Treatment of Locally Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer.

A Multi-center, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Single-Agent XXX; Following Complete Tumor Resection with or without Adjuvant Chemotherapy in Patients with Stage IB-IIA Non-Small Cell Lung Carcinoma Who Have EGFR-Positive Tumors.

A Phase III, Multi-center, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of XXX in Combination with Chemotherapy Regimens in Subjects with Previously Treated Metastatic Breast Cancer.

A Multi-center, Phase III, Randomized Placebo-Controlled Trial Evaluating the Efficacy and Safety of XXX in Combination with Chemotherapy Regimens in Subjects with Previously Untreated Metastatic Breast Cancer.

Open Label, Uncontrolled, Study of XXX in Combination with Weekly XXX in Patients with HER2 Positive Metastatic Breast Cancer.

XXX and White Blood Cells, in Bone Marrow Failure Syndromes.

A Phase 2 Study of XXX Administered Intravenously to Subjects with Non-Small Cell Lung Cancer.

A Phase 2 Study of XXX Administered Intravenously to Subjects with Recurrent Ovarian Cancer.

Randomized, Open Label, Phase II Trial Comparing XXX plus XXX to XXX Monotherapy for the Treatment of Relapsed Follicular B-Cell Lymphoma.

XXX, XXX, XXX, XXX, plus XXX and XXX, XXX, XXX, XXX, plus XXX in Patients with Diffuse Large B-Cell Lymphoma: A Phase II, Randomized, Multi-center, Comparative Trial.

A Phase II Study Using XXX combined with XXX for Treatment of Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia.

A Randomized Phase 2 Study of the Anti-Angiogenesis Agent XXX in Combinations with Chemotherapy and XXX in Patients with Metastatic Colorectal Cancer Preceded by A Phase 1 Portion.

Practice Patterns and Medical Management of Carcinoid Tumors with or without Carcinoid Syndrome: a Chart Review of 500 Patients.

A Prospective Observational Descriptive Study and Retrospective Chart Review of Subjects with Immune Thrombocytopenic Purpura ITP.

A Open Label, Safety and Tolerability Study of Deferasirox for Treatment of Transfusional Iron Overload in Low-Risk and INT-I Myelodysplastic Patients Using XXX Monitoring.

A Phase III, Multi-center, Randomized, Double-Blind, Active Controlled, Parallel Group Study of the Safety and Efficacy of the Intravenous and Oral Formulations of the Neurokinin-1 Receptor Antagonist, XXX in Combination with XXX and XXX for the Prevention of Nausea and Vomiting Induced Moderately Emetogenic Chemotherapy.

A Randomized, Double-Blind, Multi-center Study of Denosumab Compared with XXX in the Treatment of Bone Metastases in Subjects with Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma.

Phase 3 Randomized Study of XX in Combination with XXX vs. XXX as Second-line Therapy in Platinum Refractory or Resistant Ovarian Cancer.

An Open-Label Phase I Study of the Safety of XXX in Combination with XXX Malate for Patients with Advanced Cancers.

A Randomized Placebo-Controlled Study of XXX in Combination with Single Agent Chemotherapy for Metastatic Cancer Patients.

A Placebo Controlled Double Blind Trial of XXX in Combination with XXX and XXX for Patients with Metastatic Androgen Independent Prostate Cancer.

Phase II Study of XXX in Patients with Refractory and Relapsed Leukemia.

Gastrointestinal Stromal Tumors Registry Protocol.

An Observational Study of XXX in Combination with Chemotherapy for Treatment of Metastatic or Locally Advanced and Unresectable Colorectal Cancer, Locally Advanced or Metastatic Non-small Cell Lung (Excluding Predominant Squamous Cell Histology), or Locally Recurrent or Metastatic Breast Cancer.

A Phase 2 Randomized Study of XXX as A Single Agent or Intercalated with Combination Chemotherapy in Patients with Newly Diagnosed Advanced Non-Small Cell Lung Cancer Who Have Tumors with EGFR Protein Over Expression and/or Increased EGFR Gene Copy Numbers.

A Phase II, Randomized, Open-label, Pilot Study to Evaluate the Safety and the Effects on Bone Resorption of XXX in Patients with Prostate Cancer or Breast Cancer with Metastatic Bone Disease.

Prospective, Multi-national Observational Study to Assess Health Resource Utilization Associated with Skeletal Related Events in Patients with Bone Metastases Secondary to Breast, Prostate or Lung Cancer or Multiple Myeloma.

Phase 2 Randomized, Double-blind, Active-controlled Multi-center Proof of Concept Efficacy and Safety Study of XXX Alone or Combined with XXX vs XXX in Patients with Pain Due to Bone Metastases.

A Phase III Randomized, Double-blind, Active-controlled Clinical Trial to Valuate the Efficacy and Safety of XXX Plus XXX vs Placebo Plus XXX Plus XXX in Previously Untreated HER2 Positive Metastatic Breast Cancer.

Open-label, Single-arm, Multi-center Study to Evaluate the Rheumatological Tolerability of XXX as an Adjuvant Breast Cancer Treatment in Postmenopausal Women Who are Intolerant and Discontinue XXX Due to Grade 2-3 Arthralgia-myalgia.

An International Multi-centre Open-Label 2-Arm Phase III Trial of Adjuvant XXX in Triple Negative Breast Cancer.

A Randomized, Double-blind, Placebo-controlled, Multi-center, Phase 2 Study of the Efficacy and Safety of XXX in Combination with XXX and XXX in Treatment of Patients with HER2/neu+ Breast Cancer who Have Failed XXX an XXX, and a XXX.

A Phase III Open Label, Randomized Two Parallel Arm Multi-center Study of XXX vs XXX in Patients with Locally Advanced or Metastatic Breast Cancer Previously Treated with XXX and XXX and Refractory to the Most Recent Chemotherapy.

An International, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of XXX with XXX or XXX in Postmenopausal Women with Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer.

A Randomized, Phase 2 Study of XXX or XXX with XXX or XXX in Patients with Metastatic Colorectal Cancer after Failure of an XXX or XXX Containing First-line Regimen.

Phase 2, Single-arm, Open-label, Multi-center Trial of Second-line XXX Monotherapy in Patients with Metastatic or Recurrent Squamous Cell Carcinoma of the Head & Neck.

A Placebo-controlled, Double-blind, Multicenter, Randomized, Phase II Study of XXX in Previously Untreated Extensive Stage Small Cell Lung Cancer.

A Randomized, Phase III, Open-label Study of Oral loppotecan Plus Whole-brain Radiation Therapy Compared with Whole Brain Radiation Therapy Alone in Patients with Brain Metastases from Non-Small Cell Lung Cancer.

A Multi-center, Randomized, Double-blind, Controlled Phase 3, Efficacy and Safety of XXX in Patients with Advanced/ Metastatic NSCLC Treated with XXX.

A Phase IB/II, Open-label Study of the Safety, Pharmacokinetics, and Efficacy of Multiple Doses of Apo2L/TRAIL Administered Intravenously in Combination w/ Rituxan to Subjects with Low-Grade or Follicular, CD20, B-Cell Non Hodgkin's Lymphoma that has Progressed following Previous XXX Therapy.

A Randomized, Open Label Multi-center Study of XXX in Combination with XXX Q3 Compared to XXX in Combination with XXX for the Treatment of Hormone Refractory Metastatic Prostate Cancer Previously Treat with a Taxotere Containing Regimen.

A Randomized, Double-blind Phase 3 Study of XXX plus XXX vs. XXX plus Placebo for the First-line Treatment of Patients with Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.

A Phase IIb, Double-blinded, Placebo-controlled Study of Low Dose XXX and XXX Compared to Low Dose XXX and Placebo in Patients 60 Years of Age and Older with Previously Untreated AML.

A Randomized, Double-blind, Phase II Trial of XXX + XXX + XXX with or without XXX in Patient with Previously Untreated, Advanced Stage NSCLC.

Nausea & Vomiting Chemotherapy Induced.